Danish biotech giant Novo Nordisk is trading at an extremely attractive valuation — particularly relative to its main rival, ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...

In its annual 'Measuring the Return from Pharmaceutical Innovation' report based on the top 20 pharma companies by 2020 R&D ...

Viking Therapeutics VKTX announced that it has completed enrolling study participants in the phase II VENTURE-Oral Dosing ...

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

Responding to the progress of its obesity pipeline, the Chinese biotech is stepping up its investment in metabolic disease ...

Decades of research and news articles espousing an “obesity epidemic” and tons of weight-loss products launched under the ...

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Popular diabetes and weight-loss drugs known as GLP-1s are helping to boost the biopharma sector's return on investment this ...